Here are 1-3 brief analogies for BioCardia (BCDA):

• Kite Pharma for heart repair. (Kite Pharma was a pioneering cell therapy company, but for cancer. BioCardia aims to use similar advanced cell therapies to repair damaged hearts and lungs.)
• Vertex Pharmaceuticals for heart failure, but with cell therapy. (Vertex is known for developing highly specialized and transformative treatments for specific diseases. BioCardia is aiming to do the same for heart failure, using regenerative cell therapies.)

• CardiAMP Cell Therapy System: A lead therapeutic candidate for the treatment of heart failure and chronic myocardial ischemia.
• Allogeneic Cell Therapy Platform: An investigational platform utilizing culture-expanded bone marrow-derived mesenchymal cells for cardiac and pulmonary diseases.
• Helix Biotherapeutic Delivery System: A system designed to deliver therapeutics into the heart muscle using a penetrating helical needle.
• Morph Deflectable Guides and Sheaths: Medical devices used for guiding and introducing other instruments within the heart.

BioCardia, Inc. (BCDA) is a clinical-stage regenerative medicine company that develops cellular and cell-derived therapeutics and medical delivery systems. Given the highly specialized nature of its products (e.g., CardiAMP Cell Therapy System, Helix biotherapeutic delivery system, Morph deflectable guides and sheaths) and its status as a clinical-stage company, BioCardia does not sell directly to individuals. Its customers are primarily institutional or corporate entities within the healthcare and research sectors.

As a clinical-stage company, BioCardia may not have traditional "major customers" in the sense of large, recurring sales revenue, as its products are still undergoing trials and awaiting regulatory approval. However, its primary "customers" or key partners, whether for research, development, or future commercialization, would fall into the following categories:

1. Hospitals and Medical Centers: These institutions serve as sites for BioCardia's clinical trials and are the ultimate purchasers and users of its therapeutics and delivery systems once they receive regulatory approval and are commercialized.
2. Clinical Research Organizations (CROs) and Academic Research Institutions: These organizations collaborate with or are contracted by BioCardia to conduct the extensive clinical trials necessary for the development and regulatory approval of its therapies and devices.
3. Pharmaceutical and Biotechnology Companies: BioCardia may partner with or license its technology to larger pharmaceutical or biotechnology companies for co-development, manufacturing, or commercialization efforts. Such partnerships could represent a significant revenue stream and make these companies major "customers" or collaborators for BioCardia's intellectual property and products.

Peter H. Altman, Ph.D. - President, Chief Executive Officer (CEO), and Director

Dr. Altman has served as the President and CEO of BioCardia since 2002. He is recognized as the driving force behind the company's cell therapy and device strategy. He previously served as CEO (1999 to 2003) and board member (1999 to 2014) of CareDx (NASDAQ: CDNA), a company developing gene-based diagnostics for organ transplantation. Dr. Altman was also the CEO for Lumen Therapeutics from 2004 to 2005, an early-stage pharmaceutical company. He is a founder of CareDx, Inc., Lumen Therapeutics, and Sinus Rhythm Technologies, Inc. He is named inventor in 45 U.S. patents and has authored 40 scientific publications. He holds a Ph.D. in Bioengineering/Pharmaceutical Chemistry from the University of California, San Francisco and University of California, Berkeley.

David McClung - Chief Financial Officer (CFO)

Mr. McClung has been BioCardia's Chief Financial Officer since September 2017 and has been with the company since September 2013. His roles at BioCardia also included Vice President of Finance from March 2016 to August 2017 and Senior Director of Finance & Controller from September 2013 to February 2016. He possesses extensive finance and accounting experience in publicly and privately financed organizations, encompassing startups, large public companies, and middle-market businesses. Prior to joining BioCardia, Mr. McClung was Controller at NextWave Pharmaceuticals, Inc., a specialty pharmaceutical company that was acquired by Pfizer, Inc. He also served as Director of Finance and Controller at Sonitus Medical, Inc., a privately-held manufacturer. His early career involved public accounting and finance functions at Matson Navigation, Inc., The Clorox Company, and KPMG LLP. He is an actively licensed CPA.

Edward Gillis - Senior Vice President of Devices

Mr. Gillis plays a crucial role in the development and regulatory submission of BioCardia's Helix transendocardial delivery catheter.

Debby Holmes-Higgin, MPH - Vice President of Clinical

Ms. Holmes-Higgin is responsible for managing BioCardia's ongoing clinical trials, including the actively enrolling CardiAMP HF II Phase 3 trial.

Farhan Shahab - Vice President of Quality

Mr. Shahab was appointed as Vice President of Quality in November 2025, bringing over 25 years of experience in similar executive roles. He joined BioCardia from Welldoc, a digital health company, where he served as Vice President of Quality and Regulatory. His previous experience includes senior regulatory affairs and quality assurance roles at Intuity Medical, Moximed, and AngioScore. He also worked at Medtronic as Manager, Quality Engineering and Quality Systems, supporting major acquisitions.

Key Risks to BioCardia (BCDA)

1. Clinical Trial Failure and Regulatory Hurdles: As a clinical-stage regenerative medicine company, BioCardia faces significant risks related to the success of its clinical trials and subsequent regulatory approvals. The Phase 3 CardiAMP HF II trial is not guaranteed to succeed, with possibilities of unforeseen complications, adverse events, or failure to meet primary endpoints, which could severely impact the company's valuation and future prospects. A previous Phase 3 CardiAMP trial reportedly failed to meet its primary efficacy outcome using the six-minute walking test. Additionally, the dual-track regulatory strategy for both its therapeutic candidates (CardiAMP Cell Therapy System) and delivery system (Helix biotherapeutic delivery system) introduces substantial hurdles and potential delays with regulatory bodies such as the U.S. Food and Drug Administration (FDA) and Japan's Pharmaceutical and Medical Device Agency (PMDA). The inherent complexities of regenerative medicine, including the limited number of therapies that progress past early trials and concerns about long-term safety, tumor formation, and immune reactions with stem cells, further compound these risks.
2. Financial Instability and Funding Risk: BioCardia operates with a high cash burn rate, negative free cash flow, and is not expected to achieve profitability in the near term. The company has experienced significant revenue declines and deeply negative operating and net margins, with an Altman Z-Score suggesting financial distress and a high risk of bankruptcy. Its limited cash reserves provide a short operational runway, making the company highly reliant on securing additional funding or partnerships. Any setbacks or delays in clinical trials could further strain financial resources and impede the ability to raise future capital, potentially leading to stock dilution through additional share sales.
3. Intense Market Competition: BioCardia operates in a highly competitive landscape within regenerative medicine and cell therapy for cardiovascular diseases. Numerous companies and research institutions are actively developing similar breakthrough treatments. Larger pharmaceutical companies with greater financial resources and established market presence could potentially outpace BioCardia in development, marketing, and distribution. Furthermore, rapid advancements in alternative treatment modalities, such as gene therapies or novel pharmaceutical compounds, pose a threat by potentially rendering BioCardia's current approaches obsolete or less competitive.

Advancements in gene editing technologies and mRNA therapies aimed at *in-situ* cardiac repair or regeneration represent a clear emerging threat. These alternative therapeutic modalities could potentially offer less invasive or more durable solutions for conditions such as heart failure and myocardial ischemia, thereby potentially rendering BioCardia's cell transplantation approach and specialized invasive delivery systems (like the Helix biotherapeutic delivery system) less competitive or obsolete if they demonstrate superior efficacy and safety in clinical development.

BioCardia (BCDA) operates in markets related to cell therapies for cardiovascular diseases and interventional cardiology devices. The addressable markets for their main products and services include:

• CardiAMP Cell Therapy System for Heart Failure: The global advanced heart failure market was valued at USD 6.50 billion in 2024 and is projected to reach USD 27.60 billion by 2035 across the 7 major markets (United States, Germany, France, Italy, Spain, United Kingdom, and Japan), including cell-based treatments. The chronic heart failure market in the 7MM was approximately USD 8 billion in 2023. More specifically, the global cardiology stem cells market, with heart failure as a major segment, was valued at US$ 1.48 billion in 2024 and is expected to reach US$ 2.56 billion in 2033. The broader regenerative medicine market, which encompasses cell therapy for cardiovascular diseases, was valued at USD 40.51 billion globally in 2024 and is projected to reach USD 236.28 billion by 2032.
• CardiAMP Cell Therapy System for Chronic Myocardial Ischemia: The global myocardial ischemia market is estimated at USD 4.72 billion in 2025 and is expected to reach USD 7.98 billion by 2032. Another projection for the global myocardial ischemia market indicates growth from USD 4.3 billion in 2024 to USD 7.23 billion by 2030, with the U.S. market representing about 30% of this revenue, or USD 1.29 billion in 2024, increasing to USD 1.91 billion by 2030.
• Allogeneic Cell Therapy for Ischemic Systolic Heart Failure: This falls under the broader heart failure and cardiology stem cell therapy markets previously mentioned. The global cardiology stem cells market specifically aims at the repair and regeneration of damaged heart tissues, including those from ischemic cardiomyopathy.
• Allogeneic Cell Therapy for Pulmonary Disease: Information regarding the specific addressable market size for allogeneic cell therapy for pulmonary diseases was not available.
• Helix Biotherapeutic Delivery System and Morph Deflectable Guides and Sheaths: These products are categorized under interventional cardiology devices. The global interventional cardiology devices market was valued at USD 15.95 billion in 2025 and is projected to grow to approximately USD 29.9 billion by 2034. North America held the largest share of this market, at 45% in 2024. Another estimate places the global interventional cardiology devices market at USD 20.9 billion in 2025, anticipated to reach USD 46.8 billion by 2035.

BioCardia (BCDA) anticipates future revenue growth over the next 2-3 years to be driven by the following factors:

1. Commercialization of CardiAMP Cell Therapy System: The CardiAMP Cell Therapy System, an autologous treatment for ischemic heart failure, is currently in a confirmatory Phase 3b clinical trial (CardiAMP HF II). With positive clinical data indicating reductions in heart death equivalents and major adverse cardiovascular and cerebrovascular events (MACCE), particularly in high-risk patients, BioCardia is actively pursuing regulatory approval in the United States and Japan. The company plans to request a meeting with the FDA by Q4 2025 to discuss the pathway to approval, and ongoing consultations with Japan's Pharmaceuticals and Medical Devices Agency (PMDA) could lead to market entry in Japan.
2. Advancement and Potential Commercialization of CardiALLO Allogeneic Cell Therapy: BioCardia's "off-the-shelf" CardiALLO Allogeneic Cell Therapy is in a Phase I/II trial for ischemic systolic heart failure. This therapy, using universal donor mesenchymal stem cells, offers a treatment option for patients who may not be suitable for autologous therapies. Successful progression through clinical trials and subsequent regulatory approval would open a new, broader market segment for the company.
3. FDA Approval and Expanded Adoption of the Helix Biotherapeutic Delivery System: BioCardia has completed an FDA Pre-Submission for its Helix transendocardial delivery catheter, supported by data from 15 clinical trials demonstrating superior safety and efficacy in delivering cardiac therapies. Expected alignment with the FDA on the regulatory pathway within 45 days could pave the way for market clearance, potentially making Helix the first approved transendocardial delivery catheter system in the U.S. Approval and broader adoption of Helix, either as a standalone product or through partnerships with other biopharmaceutical companies, could generate significant revenue.
4. International Market Expansion, particularly in Japan: Beyond the United States, BioCardia is targeting Japan as an important initial market for its cell therapies and delivery systems. Positive consultations with the Japan PMDA regarding the CardiAMP system and the granting of a Japanese patent for the Helix delivery system underscore the potential for market approval and commercialization in Japan, contributing to international revenue growth.

Share Issuance

• The number of shares outstanding for BioCardia increased by 160.84% in one year.
• BioCardia executed a 1-for-15 reverse stock split on May 30, 2024.

Inbound Investments

• The CardiAMP HF program has received external support from entities such as the Maryland Stem Cell Research Fund and CMS.

Capital Expenditures

• Capital expenditures were approximately $2,000 in the last twelve months.
• In fiscal year 2024, BioCardia invested $6,000 in capital expenditures, representing a 50% decrease from the prior year.
• The primary focus of these capital expenditures is funding long-term assets and infrastructure.